Advanced Studies in Biology, Vol. 16, 2024, no. 1, 201 - 209
HIKARI Ltd, www.m-hikari.com
https://doi.org/10.12988/asb.2024.91966

Molecular Study of IDUA, IDS, GALNS, GLB1 Genes in Azerbaijan Republic

S. A. Alizada [1], Sh. T. Musayev[2] and E. M. Rasulov [3]

[1] Azerbaijan Medical University, Baku, AZ1022, 167 Samad Vurgun st.
cell.: (+99450)2882202
ORCID: 0000-0002-7543-0094

[2] GENOM Clinic Laboratory, Baku, White City, AZ1025, 3 Central Bulivard,
cell.:(+99451)5773819
ORCID: 0000-0002-8308-7089

[3] GENOM Clinic Laboratory, Baku, White City, AZ1025, 3 Central Bulivard,
cell.: (+99455)7711108
ORCID: 0000-0003-1363-164

Abstract

For the first time in Azerbaijan Republic, we carried out medical genetic consultation of affected children suspicious of lysosomal storage diseases, and particularly with mucopolysaccharidoses. Patients were from the cities of Baku, Gyandzhe and other areas of the Republic. Consultations were done by doctors: pediatrician and geneticist. As to clinical manifestations, 19 index patients and 54 members in their families: Hurler syndrome (1 patient), Hunter syndrome (5 patients), Morquio syndrome (13 patients). NGS (Next Generation Sequencing) technique was used for molecular genetic diagnostics.

In index patient suspicious with Hurler syndrome (MPS I) mutation of alpha-L-iduronidase (IDUA) (NP_000194,2: c.1882C>T, p.Arg628Ter) was identified in homozygous state. Among patients with clinical manifestations of Hunter syndrome (MPS II) three mutations iduronate-2-sulfatase (IDS) gene: 1106C>G (p.Asp358Leu), c.322T>G (p.Asp358Leu) and c.1215del (p.Leu*34406Phefs) were identified in hemizygous state. In patients with Morquio syndrome (MPS IVA) 9 mutations of N-acetylgalactosamine-6-sulfatase (GALBS) gene and one mutation beta-galactosidase (GLB1) c.176G-A (p.Arg59His) Morquio syndrome (MPS IVB)

were identified. Nine mutations are as follows: c.1144C>G (p.Leu382Val), c.1265A>G (p.Gln422Arg), c.463G>T (p.Gly155Cys), c.1018 G>T (p.Gly340Cys). c.157G>A (p.Gly53Arg), c.553C>T (p.Pro185Ser), c.443A>G (p.His148Arg), c.1283A>G (p.Gln428Arg), c.439T>A (p.Trp147Arg). When examining affected children family members, 41 people with heterozygous carriage of GALNS gene were identified: MPS III, MPS II-12, MPS IVA-26, relatively. In one sibling of the index patient with Morquio syndrome (MPS IVA) c.463G>T (p.Gly155Cys) mutation was found in homozygous state. Obtained experimental results allow doctors to direct patients to proper treatment as well as prophylactic activities with families including fetus prenatal diagnostics in next pregnancies.

Keywords: Hurler syndrome, Hunter syndrome, Morquio syndrome, gene, missense mutation, enzyme

Introduction

Mucopolysaccharidosis (MPS) is a group of rare lysosomal storage inherited diseases. There are several types of disease which occur because of corresponding lysosomal enzyme activity deficiency and leads to damage of glycosaminoglycans (GAG) degradation [Caciotti, A. et al., 2018; Zanetti A. et al., 2021]. MPS I (Hurler syndrome, Hurler/Scheie, Scheie) occurs because of alpha-L-iduronidase enzyme of IDUA gene, that locates in short shoulder of Chromosome 4 in locus 4p16.3. Damage of alpha-L-iduronidase enzyme activity leads to dermatan sulfate and heparan sulfate storage in body cells and tissues. Heritage type is autosome recessive (AR). Frequency of disease among live newborns is 1:100 000-1,5:500 000. Fraction of MPS I among all MPS types consists of 15% [Martins A.M. et al., 2018; Puckett Y. et al., 2021]. MPS II (Hunter syndrome) arises because of iduronate-2-sulfatase lysosomal enzyme deficiency. The given enzyme (IDS) is in the long shoulder of Chromosome X (Xq28). Heritage type is X-linked recessive (XR). Average populational frequency varies in the range 1,5-2:100 000 live newborns.

Among all MPS patients Hunter syndrome (MPS II) comprises 56% [Noh T.K. et al., 2014; Fenton-Navarro P et al., 2017]. Morquio syndrome (MPS IV) averagely consists of 10% of all affected with MPS diagnosis. The disease starts with deficiency of two lysosomal enzymes: N-acetylgalactosamine-6-sulfatase (MPS IVA) and beta-galactosidase (MPS IVB) coded by GALNS and GLB1 genes, relatively. N-acetylgalactosamine-6-sulfatase activity deficiency leads to keratan sulfate storage. The ratio of frequencies MPS IVA/MPS IVB is 6/1. Inheritance type is AR. Prevalence averagely is 1,53-2:100000 live newborns. In developed countries newborns neonatal screening is carried out for MPS complication rate [Hendriksz, C. J. et al., 2015; Filocamo, M. et al., 2018; Chien, Y. H. et al., 2020; Kubaski F. et al., 2020].

The goal of our research was identification and study of genetics of Hurler syndrome (MPS I), Hunter syndrome (MPS II) and Morquio syndrome (MPS IV) for patients from the population of Azerbaijan Republic.

Material and methods

Genetic research patients were revealed during medical genetical consultation of affected children with any clinical manifestations of mucopolysaccharidosis. Medical genetical examination of patients were carried out in presence of doctor pediatrician and doctor geneticist in children medical centers in Baku, Gyandzhe cities as well as central clinics in Sheki-Zagatala, Guba-Khachmas, Lankaran-Astara, Shirvan and Mughan economical zones of Azerbaijan Republic. Nineteen affected children with clinical manifestations of Hurler syndrome (1 index patient), five index patients with Hunter syndrome and thirteen index patients with Morquio syndrome. Alongside them fifty-four their family members were also examined.

To confirm suspicious clinic manifestations, DNA level genetic analysis was applied to. Genetic study was carried out with GSN (Next Generation Sequencing) technique. To isolate DNA, QIAamp DNA Blood mini kit (Germany manufactured) was used. Analysis was carried out on the panel designed MiSeq Illumina apparatus manufactured by Illumina® (USA). Panel included the following genes: GALNS, IDUA, IDS, GALC, SUMF1, GAA, GUSB, GBA1, GLB1, ARSB, PAH, SMPD1, ADGRV1 and PLA2G6. Sequencing of GALNS, IDUA, IDS, GBA1 genes on DNA level was identified with NGS technique (Next Generation Sequencing). There were used the following kits and programmes: kit - Lysosomal Storage Disease Kit, Celemics®; Analysis Platform - MiSeq Sequencing, Illumina®; Analysis programme - SEQ analysis platform, GENOMIZE® (http://seq.genomize.com), GRCh37(h19) [Alizada S.A. and Rasulov E.M., 2023].

"DNA samples with their gene mutations were identified on that panel with Next Generation Sequencing technique. More than 99% gene coding sites were studied with reading depth of not less than 50X. Mean reading depth was 1559 indications. Analysis included exon-intron linkage (±10 np)." The pathogeny classification of the obtained results was conducted correspondently to "Guidelines of ACMG®".

Results and discussion

Our results of molecular genetical studies of affected children with Hurler, Hunter and Morquio diseases are presented in Table 1. There are presented types of mucopolysaccharidoses syndromes as well as genes, mutation types on gene and synthesized protein levels, gene pathogeny rate, and gene location in chromosome and its heritance type.

An affected kid with Hurler syndrome had got nucleotide change of Cytosine to Thymine in position 1882 of exon 1 in IDUA gene in homozygous state (c.1882C>T/c.1882C>T). In consequence of missense mutation/nonsense mutation in newly synthesized protein, a substitution occurred - Arginine amino acid changed with Tyrosine in position 628 (NP_000194.2: p.Arg628Ter). The parents of the affected kid were cousins.

Nevertheless, population of Azerbaijan Republic and Islamic Republic of Iran have intrinsic ethnic factors in subgroups, there were none among identified

patients with Hurler syndrome having c. 1882C>T IDUA gene mutation. However, the given mutation was found among patients in Republic of Turkey and was one of ten identified mutations of IDUA gene [Church H. et al., 2013; Atçeken N. et al., 2016].

It was established that the most spread type of changes (56,9%) in IDUA gene was missense mutation/nonsense mutation. Authors studied 292 IDUA genes and managed to find out the following mutation types: splicing -15,8%, regulator - 0,3%, small deletion, small insertion - 23,6%, large deletion, large insertion - 2,4%, complex rearrangements - 1% [Puckett Y. et al., 2021].

As to the description of Alshahran H. et al. (2023) for MPS I screening of 618 newborns in Kuwait was carried out in course of 2021-2022 years to evaluate activity levels for alpha-L-iduronidase enzyme.

Enzyme deficiency was stated to be present in 20 newborns. Molecular study of newborns with enzyme deficit identified IDUA gene c.1882C>T mutation. Frequency of MPS I in the USA was 0,29:100,000 live newborns. In some countries of the world neonatal screening of newborns is being held for presence of MPS I [Hendriksz, C.J.et al., 2015; Galimberti, C. et al., 2018].

Three mutations of IDS gene were identified in five patients during our studies. They had diagnosed as MPS II: c.1106C>G (p.Asp358Leu), c.322T>G (p.Asp358Leu) and c.1215del (p.Leu*34406Phefs). They were two missense/nonsense mutations and one deletion.

Kubaski F. et al. (2020) in studies of 659 affected patients with Hunter syndrome stated the highest frequency of missense mutation/nonsense mutation of IDS gene (49,8%). The rest mutation types were distributed as follows: splicing - 9,3%, regulator - 0%, small deletion, small insertion - 11,5%, large insertion, large deletion - 8,8%, complex re arrangement - 3%.

When examining Taiwan specifically screening iduronate-2-sulfatase enzyme activity authors found 195 cases of the disease. At the same time 140 asymptomatic cases were revealed. Genetical analysis stated 19 new mutations including c.1106C>G (p.Asp358Leu) [Lin H.Y. et al.,2009].

The genetic mutation c.322 T>G is also one of the many mutations linked with Hunter syndrome. This disease is faced mainly in male patients. It leads to damage to various parts of the human body. This mutation causes tyrosine-to-aspartic acid change in position 108. That change damages the ability to break down GAGs.

If compared the frequency of Hunter syndrome all over the world, we could come across the following statistics: up to year 2017, the first place with Hunter syndrome was taken by the USA. There were found 503 cases with the said syndrome. The second place was given to Japan (309 cases). It is known that Asian countries as Japan, China, Korea and Taiwan have relatively high severity of Hunter syndrome. The severity could vary. The next are coming five countries of the European Union: United Kingdom, Spain, Italy, Germany and France. Data available for now is known as dated back to 2017, not later. For those days Germany had the most frequency of identified cases (83 people) followed by United Kingdom (68 cases).

Table 1. Identified IDUA, IDS, GALNS AND GLB1 genes mutations in Azerbaijan.

MPS type	Gene, Mutation	Protein	Pathogeny	Chromosome, Inheritance type
MPS I Hurler syndrome	IDUA: alpha-L-iduronidase NM_000203.5: c.1882 C>T; Exon 1	p.Arg628Ter	Pathogenic (class 2)	Chr 4p16.3, AR
MPS II Hunter syndrome	IDS: iduronate 2-sulfatase NM_000202.5: c.1215del	p.Leu*34406 Phefs	Pathogenic (class 1)	Chr Xq28, X-R
MPS II Hunter syndrome	IDS: iduronate-2-sulfatase. NM_000202.5: c.322T>G	p.Tyr108Asp	Pathogenic (class 1)	Chr Xq28, X-R
MPS II Hunter syndrome	IDS: iduronate-2-sulfatase. NM_000202.5: c.1106C>G	p.Asp358Leu	Pathogenic (class 1)	Chr Xq28, X-R
MPS IVA Morquio syndrome	GALNS: N-acetyl galactosamine 6-sulfatase, NM_001323544.1: c.1144C>G	p.Leu382Val	Pathogenic (class 1)	Chr 16q24.3, AR
MPS IVB Morquio syndrome	GLB1 beta-galactosidase, NM_000404.4; c.176G>A; Exon	p.Arg59His	Pathogenic (class 1)	Chr 3p22.3, AR
MPS IVA Morquio syndrome	GALNS: N-acetyl galactosamine 6-sulfatase, ENST00000268695, c.1265A>G	p.Gln422Arg	Pathogenic (class 1)	Chr 16q24.3, AR
MPS IVA Morquio syndrome	GALNS:ENSG00000141012-NM-0011323543, c.463G>T	p.Gly155Cys	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IVA Morquio syndrome	GALNS:ENSG00000141012-ENST00000268695, c.1018 G>T	p.Gly340Cys	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IV Morquio syndrome	GALNS NM_001323544.1: c.157G>A	p.Gly53Arg	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IVA Morquio syndrome	GALNS: NM_001323544.1: c.553C>T	p.Pro185Ser	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IVA Morquio syndrome	GALNS:NM_001323544.1:c.443A>G Exon 5	p.His148Arg	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IVA Morquio syndrome	GALNS:NM_001323544.1: c.1283A>G	p.Gln428Arg	Pathogenic (class 1)	Chr -16q24.3, AR
MPS IVA Morquio syndrome	GALNS:NM_001323544.1: c.439T>A	p.Trp147Arg	Pathogenic (class 1)	Chr -16q24.3, AR

Genetical analysis of GALNS gene for 13 affected children with clinical manifestations of Morquio syndrome resulted in the following nine mutations: c.1144C>G (p.Leu382Val), c.1265A>G (p.Gln422Arg), c.463G>T (p.Gly155Cys), c.1018G>T (p.Gly340Cys), c.157G>A (p.Gly53Arg), c.553C>T (p.Pro185Ser), c.443A>G (p.His148Arg), c.1283A>G (p.Gln428Arg), c.439T>A (p.Trp147Arg). All nine GALNS gene mutations had missense mutations. Clinical variety of Morquio syndrome in patients from Azerbaijan Republic could be explained with GALNS gene mutation variety. In one patient GLBI gene was identified with its mutation c.176G>A (p.Arg59His).

At the same time, we consulted and analyzed genetically 41 people with heterozygous carriage: MPS I-3 people, MPS II-12 people, MPS IV-26 people, relatively. One sibling was found to have GALNS gene mutation: c. 463G>T (p.Gly155Cys) in homozygous state (MPS IVA).

Our studies revealed gene level one mutation type - missense mutation/nonsense mutation in all affected children with MPS IVA and MPS IVB, that was the most spread mutation types. Kubaski F. et al., 2020 found that in genetical studies of patients with MPS I and MPS II syndromes in both genes: GALNS и GLB1 missense mutation/nonsense mutation type prevailed as 74,4% and 76%, relatively. Authors at that time examined 556 cases. The second mutation type for MPS IV both types was large deletion/large insertion 11,5% and 15,4%, relatively. Small deletion/small insertion takes the third position: 9,8% and 7,3%.

GALNS mutations' heterozygosity explains vast clinical variability of MPS IVA. More than 300 mutations of the gene are identified and described, they are as follows: 78,4% linked with missense mutations, 9,2% with small deletions, 5,0% with nonsense mutations, 2,4% with large deletions, 1,6% with insertions, small and large deletions, and transversions (Hendriksz, C. J. et al., 2015). Incidence of Morquio syndrome in different populations varies. Khan et al., (2017) when screening of newborns in Japan and Sweden during years of 1982-2009 469 affected patients were found and diagnosed with MPS of all types and frequency was 1,5:100000 live newborns. 55% of them related to MPS II (0,8:100 000). Frequency of MPS I and MPS II was counted as 15% and 10%, relatively. In Sweden retrospective epidemiological analysis was carried out for a period of 34 years, where genetical analyses of 41 patients were run. 12% of patients had got MPS I diagnosis, and 24% - MPS IV. In populations of Eastern Asia, Germany, Northern Ireland, Portugal and Netherlands, MPS II prevailed highly up to 50%. It should be mentioned that in the above enumerated countries other MPS types were also vast spread. Differing from those said countries epidemiological data in Turkey showed quite distinguished picture. 339 affected people with MPS diagnoses were distributed in following order: MPS I -7,79%, MPS II - 14,29%, MPS III - 28,57%, MPS IV - 28,57%, MPS VI - 18,48%, and MPS VII - 1,29%. Turks resided in Germany two type of MPS were found: MPS IIIB -33% and MPS IV -22. There were screenings of live newborns in the USA for 20 years, and frequency consisted as 0,98:100 000. Around 2,67 affected kids in every million newborns. Frequency of MPS I, MPS II and MPS III prevailed (0,26:100 000 and 0,70-0,71). Frequency of MPS IV, MPS VI and MPS VII were lower - 0,14; 0,04 and 0,02 relatively, i.e.

per 100 000 live newborns [Church H. et al., 2013; Chen X. Et al., 2016; Atçeken N. et al., 2016; Khan, S. et al., 2017; Caciotti, A. et al., 2018; Puckett Y. 2021; Zanetti A. et al., 2021].

Conclusions

Hence, when medical genetical consultation of affected patients suspicious with lysosomal storage diseases, especially mucopolysaccharidoses, we first time in Azerbaijan Republic identified and genetically studied 19 affected patients and 54 their family members. One index patient suspicious with Hurler syndrome (MPS I) identified missense mutation of IDUA gene (NP_000194,2: c.1882C>T, p.Arg628Ter) in homozygous state. Three mutations of IDS gene were identified: two missense mutations 1106C>G (p.Asp358Leu), c.322T>G (p.Asp358Leu) and one deletion c.1215del (p.Leu*34406Phefs) in hemizygous. In patients with Morquio syndrome (MPS IVA) nine GALBS gene missense mutations were identified: c.1144C>G (p.Leu382Val), c.1265A>G (p.Gln422Arg), c.463G>T (p.Gly155Cys), c.1018 G>T (p.Gly340Cys), c.157G>A (p.Gly53Arg), c.553C>T (p.Pro185Ser), c.443A>G (p.His148Arg), c.1283A>G (p.Gln428Arg), c.439T>A (p.Trp147Arg) and one missense mutation of GLB1 gene - c.176G>A (p.Arg59His) that was responsible for Morquio syndrome (MPS IVB). Identified missense mutations were in homozygous and double heterozygous (compound) states. When examining family members of affected index patients, we found out 41 people with heterozygous carriage of genes: 3 people with IDUA gene (MPS I) carriage, 12 people with IDS gene (MPS II) carriage, 26 people with GALNS gene (MPS IVA) carriage. At the same time when examining family members, a sibling of an index patient's with Morquio syndrome (MPS IVA) identified c.463G>T (p. Gly155Cys) in a homozygous state.

Considering the reproductive age of parents, fetus prenatal diagnostics is being planned for the next pregnancies.

References

[1] Alizade S.A. and Rasulov E.M. Sanfilippo, A syndrome genetic studies in the patient Azerbaijan Republic, *Khazar J. of Science and Technology*, **7** (2023), no. 2, 28-36.

[2] Alessandra Zanetti, Francesca D'Avanzo, Moeenaldeen AlSayed, Ana Carolina Brusius-Facchin, Yin-Hsiu Chien, Roberto Giugliani, Emanuela Izzo, David C. Kasper, Hsiang-Yu Lin, Shuan-Pei Lin, Laura Pollard, Akashdeep Singh, Rodolfo Tonin, Tim Wood, Amelia Morrone, and Rosella Tomanin, Molecular basis of mucopolysaccharidosis IVA (Morquio A syndrome): A review and classification of GALNS gene variants and reporting of 68 novel variants, *Hum Mutat.*, **42** (2021), no. 11, 1384-1398. https://doi.org/10.1002/humu.24270

[3] Caciotti, A., Tonin, R., Mort, M., Cooper, D. N., Gasperini, S., Rigoldi, M., Parini, R., Deodato, F., Taurisano, R., Sibilio, M., Parenti, G., Guerrini, R., & Morrone, A. (2018). Mis-splicing of the GALNS gene resulting from deep intronic mutations as a cause of Morquio a disease, *BMC Medical Genetics*, **19** (2018), 183. https://doi.org/10.1186/s12881-018-0694-6

[4] Chen X., Qiu W., Ye J., Han L., Gu X., Zhang H, Demographic characteristics and distribution of lysosomal storage disorder subtypes in Eastern China, *J. Hum. Genet.*, **61** (2016), 345-349. https://doi.org/10.1038/jhg.2015.155

[5] Chien, Y.H., Lee, N.C., Chen, P.W., Yeh, H.Y., Gelb, M.H., Chiu, P.C., Chu, S.Y., Lee, C.H., Lee, A.R., & Hwu, W.L., Newborn screening for Morquio disease and other lysosomal storage diseases: Results from the 8-plex assay for 70,000 newborns, *Orphanet Journal of Rare Diseases*, **15** (2020), 38. https://doi.org/10.1186/s13023-020-1322-z

[6] Filocamo, M., Tomanin, R., Bertola, F., & Morrone, A., Biochemical and molecular analysis in mucopolysaccharidoses: What a paediatrician must know, *Italian Journal of Pediatrics*, **44** (2018), 129. https://doi.org/10.1186/s13052-018-0553-2

[7] Francyne Kubaski, Fabiano de Oliveira Poswar, Kristiane Michelin-Tirelli, Maira Graeff Burin, Diana Rojas-Málaga, Ana Carolina Brusius-Facchin, Sandra Leistner-Segal, Roberto Giugliani, Diagnosis of Mucopolysaccharidoses, *Diagnostics (Basel).* **10** 2020), no. 3, 172. https://doi.org/10.3390/diagnostics10030172

[8] Galimberti, C., Madeo, A., Di Rocco, M., & Fiumara, A., Mucopolysaccharidoses: Early diagnostic signs in infants and children, *Italian Journal of Pediatrics*, **44** (2018), 133. https://doi.org/10.1186/s13052-018-0550-5

[9] Heather Church, June Petty, Jessica Righart, Oliver Parkes, Christine Egerton, Wendy Savage, Karen Tylee. The incidence of mucopolysaccharidoses and related disorders in the Turkish population: A 3 year study, Molecular Genetics and Metabolism, **108** (2013), no. 2, S30. http://dx.doi.org/10.1016/j.ymgme.2012.11.055

[10] Hendriksz, C.J., Berger, K.I., Giugliani, R., Harmatz, P., Kampmann, C., Mackenzie, W.G., Raiman, J., Villarreal, M.S., & Savarirayan, R. International guidelines for the management and treatment of Morquio A syndrome, *American Journal of Medical Genetics Part A*, **167** (2015), 11-25. https://doi.org/10.1002/ajmg.a.36833

[11] Khan, S., Alméciga-Díaz, C.J., Sawamoto, K., Mackenzie, W.G., Theroux, M.C., Pizarro, C., Mason, R.W., Orii, T., & Tomatsu, S., Mucopoly-saccharidosis

IVA and glycosaminoglycans, *Molecular Genetics and Metabolism*, **120** (2017), 78-95. https://doi.org/10.1016/j.ymgme.2016.11.007

[12] Lin H.Y., Lin S.P., Chuang C.K., Niu D.M., Chen M.R., Tsai F.J., Chao M.C., Chiu P.C., Lin S.J., Tsai L.P., et al. Incidence of the Mucopolysaccharidoses in Taiwan, 1984-2004, *Am. J. Med. Genet. Part. A.* **149** (2009), 960-964. https://doi.org/10.1002/ajmg.a.32781

[13] Martins A.M., Lindstrom K., Kyosen S.O., Munoz-Rojas M.V., Thibault N., Polgreen L.E. Short stature as a presenting symptom of attenuated Mucopolysaccharidosis type I: case report and clinical insights, *BMC Endocr. Disord.*, **18** (2018), 83. https://doi.org/10.1186/s12902-018-0311-x

[14] Nazente Atçeken, Riza Koksal Özgül, Didem Yüsel Yılmaz, Ayşegül Tokatlı. Evaluation and identification of IDUA gene mutations in Turkishpatients with mucopolysaccharidosis type I, *Turkish Journal of Medical Sciences*, **46** (2016), no. 2, 404-408. https://doi.org/10.3906/sag-1411-160

[15] Noh T.K., Han J.S., Won C.H., Chang S., Choi J.H., Moon K.C., Lee M.W., Yang J.H., Soung J.H., Characteristic "pebbling" skin eruption as a presenting sign of Hunter syndrome, *Int. J. Dermatol.*, **53** (2014), e594-e596. https://doi.org/10.1111/ijd.12206

[16] Patricia Fenton-Navarro, Eduardo L Perez-Campos, Socorro Pina Canseco Bertha Fenton-Navarro, Gaucher's Disease and Hurler's Syndrome in Two First Cousins, *International Journal of Human Genetics*, **17** (2017), no. 3, 109-117. http://dx.doi.org/10.1080/09723757.2017.1365433

[17] Yana Puckett, Alejandra Mallorga-Hernández & Adriana M. Montaño, Epidemiology of mucopolysaccharidoses (MPS) in United States: challenges. Orphanet, *Journal of Rare Diseases*, **16** (2021), no. 24. https://doi.org/10.1186/s13023-021-01880-8

Received: December 1, 2024; Published: December 16, 2024